New data on Novo’s next-gen obesity drugs and hemophilia challenger

23 June 2025

Danish drugmaker Novo Nordisk (NOV: N) has released fresh clinical data on two of its lead investigational assets, seeking to bolster its strong position in obesity while moving to challenge in rare blood disorders.

Results published in The New England Journal of Medicine and presented showed that once-weekly CagriSema — a fixed-dose combination of semaglutide and the amylin analogue cagrilintide — helped patients without diabetes but with a weight-related condition shed around 23% of their body weight over 68 weeks. The results were part of the phase III REDEFINE 1 study, which met both co-primary endpoints.

Novo is also pursuing a parallel path in people with obesity and type 2 diabetes. In the REDEFINE 2 trial, CagriSema led to average weight loss of 15.7% over the same duration among those who remained on treatment, compared to 3.1% for placebo. A greater share of participants in the CagriSema group reached key thresholds of 10%, 15% and 20% weight loss.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK